Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

Targeted Therapy Better than Immunotherapy in Some Patients with NSCLC

Posted on February 5, 2024
Post Views: 272

Lung CancerNon-small cell lung cancer continues to remain one of the main reasons behind cancer related deaths all across the world. Continuous studies and research works are going on that could help in its early detection and better cure. The researchers at Yale Cancer Center have recently reported in the Journal of Thoracic Oncology that the targeted therapy Osimertinib is associated with significantly improved progression free survival.

In this retrospective study, they utilize data from 2015 through 2022 involving 136 stage III NSCLC patients with EGFR mutation. The team compared the survival outcomes achieved after taking Osimertinib, Durvalumab or neither treatment after chemo and radiation. In the study, they found that 86% patients treated with Osimertinib lived at least two years without getting their condition worsened. This was higher than patients who were treated with Durvalumab (30%) and who took neither treatment (27%). Thus, NSCLC with EGFR mutations responded poorly to immunotherapy treatments, including Durvalumab.

Talking about the associated side effects, only 6% of patients treated with Osimertinib in comparison to 18% of patients treated with Durvalumab. Also, no unexpected safety risks were found during the study.

Non-Small-Cell Lung Cancer (NSCLC)Amin Nassar, co-first author on the study and member of YCC said, “Osimertinib is a drug that is actually very specific for the EGFR mutation itself.” “It has proven to be very efficacious in the stage IV setting and also, more recently with the ADAURA trial, in the stage III setting. We wanted to find out in the unresectable [tumor not removable with surgery] stage III population, are we going to see similar benefits? And is this targeted therapy actually better than immunotherapy for these specific patients?”

He also said that there need to be larger studies to determine the overall survival benefit of Osimertinib as a post remission therapy for this unresectable, NSCLC EGFR-mutant patient population.

The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical issues.

Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d